Results: 13
Taiwan Nationwide Study of First-Line ALK–TKI Therapy in ALK-Positive Lung Adenocarcinoma.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 6, p. 941, doi. 10.1007/s11523-024-01104-6
- By:
- Publication type:
- Article
Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-Pacific.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 6, p. 917, doi. 10.1007/s11523-024-01103-7
- By:
- Publication type:
- Article
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 6, p. 879, doi. 10.1007/s11523-024-01102-8
- By:
- Publication type:
- Article
Physician Perspectives on the Management of Patients with Resected High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Who Are Ineligible to Receive Cisplatin: A Podcast.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 6, p. 981, doi. 10.1007/s11523-024-01100-w
- By:
- Publication type:
- Article
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 6, p. 905, doi. 10.1007/s11523-024-01099-0
- By:
- Publication type:
- Article
Pancreatitis in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 6, p. 867, doi. 10.1007/s11523-024-01098-1
- By:
- Publication type:
- Article
Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 6, p. 845, doi. 10.1007/s11523-024-01097-2
- By:
- Publication type:
- Article
Real-Life Experience with Entrectinib in Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Solid Tumors: A Multicenter Retrospective Trial.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 6, p. 957, doi. 10.1007/s11523-024-01095-4
- By:
- Publication type:
- Article
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 6, p. 925, doi. 10.1007/s11523-024-01094-5
- By:
- Publication type:
- Article
Evaluation of Drug–Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model
- Published in:
- Targeted Oncology, 2024, v. 19, n. 6, p. 965, doi. 10.1007/s11523-024-01093-6
- By:
- Publication type:
- Article
The Epidemiology of Biliary Tract Cancer and Associated Prevalence of MDM2 Amplification: A Targeted Literature Review.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 6, p. 833, doi. 10.1007/s11523-024-01086-5
- By:
- Publication type:
- Article
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).
- Published in:
- Targeted Oncology, 2024, v. 19, n. 6, p. 893, doi. 10.1007/s11523-024-01096-3
- By:
- Publication type:
- Article